Analysts Set MorphoSys AG Price Target at 14.00
Slightly above 67% of MorphoSys' investor base is looking to short. The analysis of current outlook of investing in MorphoSys AG ADR suggests that many traders are alarmed regarding MorphoSys' prospects. MorphoSys' investing sentiment overview a quick insight into current market opportunities from investing in MorphoSys AG ADR. Many technical investors use MorphoSys AG ADR stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
MorphoSys |
Shares of MorphoSys AG have earned a consensus rating of Hold from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to
Read at thelincolnianonline.com
 |
MorphoSys Fundamental Analysis
We analyze MorphoSys' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MorphoSys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MorphoSys based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Profit Margin
Profit Margin Comparative Analysis
MorphoSys is currently under evaluation in profit margin category among its peers. Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
MorphoSys AG ADR Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MorphoSys stock to make a market-neutral strategy. Peer analysis of MorphoSys could also be used in its relative valuation, which is a method of valuing MorphoSys by comparing valuation metrics with similar companies.
Peers
MorphoSys Related Equities
| PCVX | Vaxcyte | 14.27 | ||||
| GLUE | Monte Rosa | 12.23 | ||||
| ELVN | Enliven Therapeutics | 10.75 | ||||
| GOSS | Gossamer Bio | 8.24 | ||||
| CCCC | C4 Therapeutics | 8.02 | ||||
| MLYS | Mineralys Therapeutics, | 7.79 | ||||
| ACLX | Arcellx | 4.42 | ||||
| KRON | Kronos Bio | 3.16 | ||||
| IMCR | Immunocore Holdings | 3.08 | ||||
| PMVP | Pmv Pharmaceuticals | 2.96 | ||||
| EWTX | Edgewise Therapeutics | 2.47 | ||||
| CGEM | Cullinan Oncology | 1.70 | ||||
| MRSN | Mersana Therapeutics | 1.59 | ||||
| GBIO | Generation Bio | 1.14 | ||||
| RLYB | Rallybio Corp | 1.12 | ||||
| VTYX | Ventyx Biosciences | 1.03 | ||||
| REPL | Replimune | 0.67 | ||||
| IMRX | Immuneering Corp | 2.56 | ||||
| IPSC | Century Therapeutics | 3.09 | ||||
| NVCT | Nuvectis Pharma | 4.79 | ||||
| LYRA | Lyra Therapeutics | 5.00 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in MorphoSys Stock
If you are still planning to invest in MorphoSys AG ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MorphoSys' history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |